Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway
BACKGROUND VEGF signaling pathway inhibitor (anti‐VEGF) therapy is associated with
hypertension, but little is known about predisposing clinical characteristics. This study …
hypertension, but little is known about predisposing clinical characteristics. This study …
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway
OPR Hamnvik, TK Choueiri, A Turchin, RR McKay… - Cancer, 2015 - infona.pl
BACKGROUND VEGF signaling pathway inhibitor (anti‐VEGF) therapy is associated with
hypertension, but little is known about predisposing clinical characteristics. This study …
hypertension, but little is known about predisposing clinical characteristics. This study …
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.
OPR Hamnvik, TK Choueiri, A Turchin… - Cancer …, 2015 - search.ebscohost.com
BACKGROUND VEGF signaling pathway inhibitor (anti-VEGF) therapy is associated with
hypertension, but little is known about predisposing clinical characteristics. This study …
hypertension, but little is known about predisposing clinical characteristics. This study …
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway
OPR Hamnvik, TK Choueiri, A Turchin, RR McKay… - Cancer, 2014 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> BACKGROUND</jats: title>< jats: p> VEGF signaling pathway
inhibitor (anti‐VEGF) therapy is associated with hypertension, but little is known about …
inhibitor (anti‐VEGF) therapy is associated with hypertension, but little is known about …
[HTML][HTML] Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway
OPR Hamnvik, TK Choueiri, A Turchin, RR McKay… - Cancer, 2015 - ncbi.nlm.nih.gov
Background VEGF signaling pathway inhibitor (anti-VEGF) therapy is associated with
hypertension, but little is known about predisposing clinical characteristics. This study …
hypertension, but little is known about predisposing clinical characteristics. This study …
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.
OP Hamnvik, TK Choueiri, A Turchin, RR McKay… - Cancer, 2014 - europepmc.org
Background VEGF signaling pathway inhibitor (anti-VEGF) therapy is associated with
hypertension, but little is known about predisposing clinical characteristics. This study …
hypertension, but little is known about predisposing clinical characteristics. This study …
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway
OPR Hamnvik, TK Choueiri, A Turchin… - Cancer, 2015 - pubmed.ncbi.nlm.nih.gov
Background VEGF signaling pathway inhibitor (anti-VEGF) therapy is associated with
hypertension, but little is known about predisposing clinical characteristics. This study …
hypertension, but little is known about predisposing clinical characteristics. This study …